. Author manuscript; available in PMC: 2023 Feb 10.

Published in final edited form as: Clin Infect Dis. 2022 Jul 5;76(3):e920–e929. doi: 10.1093/cid/ciac556

Table 3. Sequencing of MTBDRsl targets (gyrA, rrs) to resolve results discrepant with pDST. Most fluoroquinolone discrepants resolved in favour of MTBDRsl whereas most SLIDs discrepants resolved in favour of pDST.

				Sequencing
Locus		MTBDRsl	pDST	Mutation	No. isolates	Susceptibility result	Resolved in favour of LPA or pDST
Fluoroquinolones	*gyrA*(n=11)	S	R	G81C^*	1	S	MTBDRsl
				A88T	1	R	pDST
				WT	9	S	MTBDRsl
	(n=24)	R	S	A88T	1	R	MTBDRsl
				C86T	1	R	MTBDRsl
				D89N	1	R	MTBDRsl
				A90V	4	R	MTBDRsl
				S91P	1	R	MTBDRsl
				D94G	2	R	MTBDRsl
				S95T^{^}	2	S	pDST
				WT	6	S	pDST
				NR	6
	Discrepant resolution by sequencing			69% (20/29) in favour of MTBDRsl 31% (9/29) in favour of pDST
Second-line injectables	*rrs*(n=6)	S	R	WT	3	S	MTBDRsl
	*rrs*(n=6)	S	R	NR	3
	(n=22)	R	S	WT	8	S	pDST
				A1401G	1	R	MTBDRsl
				NR	13
	Discrepant resolution by sequencing	33% (4/12) in favour of MTBDRsl 67% (8/12) in favour of pDST

G81C - silent mutation

^{^}

S95T – does not cause resistance [28, 29]

Abbreviation: R-resistant, S-susceptible, WT-wild-type, NR-number of specimens that did not amplify for sequencing, n-number, pDST-phenotypic drug susceptibility testing, LPA-line probe assay